Changes in vertically transmitted human immunodeficiency virus infection Chile

被引:0
作者
Ana Chavez, P. [1 ]
Ana M. Alvarez, P. [2 ]
Elba Wu, H. [2 ]
Anamaria Pena, D. [3 ]
Eloisa Vizueta, R. [4 ]
Pediat, Sociedad Chilena
机构
[1] Hosp Dr Exequiel Gonzalez Cortes, Santiago, Chile
[2] Hosp San Juan Dios, Santiago, Chile
[3] Hosp Dr Sotero del Rio, Santiago, Chile
[4] Hosp San Borja Arriaran, Santiago, Chile
来源
REVISTA CHILENA DE INFECTOLOGIA | 2007年 / 24卷 / 05期
关键词
human immunodeficiency virus; vertical transmission; prophylaxis;
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The identification of various risk factors of vertical human immunodeficiency virus (HIV) transmission resulted in the development of strategies whose aim was to decrease the mother's viral load, to reduce her child's exposure to it during delivery, and to avoid the subsequent viral exposure due to breastfeeding. The administration of antiretroviral treatment during pregnancy, delivery and to the neonate (PACTG 076) proved to be useful. At a first stage, zidovudine was used. A triple combination therapy was then administered. Initially, the viral transmission in mothers who were enrolled in protocols for vertically transmitted HIV prophylaxis was reduced to 9.5%, whereas the last measurement carried out between 1998 and 2005, the initial figure was brought down to 2%. Nevertheless, the delivery of infected children whose mother's HIV status was unknown is still considered likely to happen. The main step to be taken to reduce HIV infection among children is to perform universal HIV tests during pregnancy, so that HIV positive pregnant patients conveniently receive proper prophylaxis. We look forward to achieving this by following the new prevention guidelines of vertically-transmitted HIV infection, developed by the Comision Nacional del SIDA of the Chilean Health Ministry.
引用
收藏
页码:368 / 371
页数:4
相关论文
共 10 条
[1]  
Abarzúa C Fernando, 2005, Rev. chil. infectol., V22, P327
[2]   The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1 -: A meta-analysis of 15 prospective cohort studies [J].
Andiman, W ;
Boucher, M ;
Burns, D ;
Bryson, Y ;
Farley, J ;
Fowler, H ;
Gabiano, C ;
Galli, L ;
Hutto, C ;
Kind, C ;
Korber, B ;
Kovacs, A ;
Krogstad, P ;
Landesman, S ;
Lapointe, N ;
Lemay, M ;
Lew, J ;
Mandelbrot, L ;
Mayaux, MJ ;
Mellins, R ;
Minkoff, H ;
Mofenson, L ;
Nielsen, K ;
Newell, ML ;
Pardi, G ;
Peavy, H ;
Peckham, C ;
Read, J ;
Rother, C ;
Rudin, C ;
Scott, G ;
Semprini, A ;
Shearer, W ;
Simonds, R ;
Simpson, B ;
Stek, A ;
Tovo, PA ;
Tuomala, R ;
Van Dyke, R ;
Weedon, J ;
de Martino, M ;
Lindsay, M ;
Belair, S ;
Chan, L ;
Harris, D ;
Kalish, L ;
Muenz, L ;
Nugent, R ;
Schluchter, M ;
Durako, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (13) :977-987
[3]  
Beltrán Buendía Carlos J, 2005, Rev. chil. infectol., V22, P295
[4]  
CHAVEZ A, 2000, REV CHIL INFECTOL, V17, P297
[5]  
CHAVEZ A, 2000, REV CHIL INFECT, V17, P302
[6]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[7]  
Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287
[8]  
*MIN SAL, 2005, GUIA CLIN SINDR IMM
[9]  
*PUBL HLTH SERV TA, 2006, REC US ANT DRUGS PRE
[10]   Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant [J].
Sperling, RS ;
Shapiro, DE ;
Coombs, RW ;
Todd, JA ;
Herman, SA ;
McSherry, GD ;
OSullivan, MJ ;
VanDyke, RB ;
Jimenez, E ;
Rouzioux, C ;
Flynn, PM ;
Sullivan, JL ;
Spector, SA ;
Diaz, C ;
Rooney, J ;
Balsley, J ;
Gelber, RD ;
Connor, EM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (22) :1621-1629